US COST-EFFECTIVENESS OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV

被引：0
|
作者：
Vardanega, V. [1 ]
New, E. [1 ]
Mezzio, D. [2 ]
Eddowes, L. A. [1 ]
机构：
[1] Costello Med, London, England
[2] Gilead Sci, Foster City, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE472
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [41] Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
    Ye, Dongmei
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [42] COST-EFFECTIVENESS OF APALUTAMIDE plus ADT VERSUS ENZALUTAMIDE plus ADT IN NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN GREECE
    Tsiatas, M.
    van Oostrum, I
    Tritaki, G.
    Sermon, J.
    Chatzimouratidis, K.
    VALUE IN HEALTH, 2019, 22 : S478 - S478
  • [43] Cost-effectiveness of olanzapine versus generic risperidone and other antipsychotics in standard oral formulations in patients with schizophrenia in the US
    Ascher-Svanum, H.
    Furiak, N. M.
    Klein, R. W.
    Smolen, L. J.
    Zhu, B.
    VALUE IN HEALTH, 2007, 10 (06) : A294 - A294
  • [44] Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis
    Evans, Denise
    Hirasen, Kamban
    Ramushu, Clive
    Long, Lawrence
    Sinanovic, Edina
    Conradie, Francesca
    Howell, Pauline
    Padanilam, Xavier
    Ferreira, Hannetjie
    Variaiva, Ebrahim
    Rajaram, Shakira
    Gupta, Aastha
    Juneja, Sandeep
    Ndjeka, Norbert
    PLOS ONE, 2024, 19 (10):
  • [45] COST-EFFECTIVENESS OF PRETOMANID-BASED REGIMEN FOR TREATMENT OF HIGHLY DRUG-RESISTANT TUBERCULOSIS IN A HIGH-INCOME COUNTRY
    Fekadu, G.
    Wang, Y.
    You, J. H. S.
    VALUE IN HEALTH, 2023, 26 (06) : S117 - S117
  • [46] Assisted reproductive treatments versus unprotected intercourse to achieve pregnancy for HIV serodiscordant couples: A cost-effectiveness analysis.
    O'Brien, J. E.
    Bryant, A.
    Milad, M. P.
    FERTILITY AND STERILITY, 2006, 86 : S366 - S367
  • [47] Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis
    Ionescu, Ana-Maria
    Agnarson, Abela Mpobela
    Kambili, Chrispin
    Metz, Laurent
    Kfoury, Jonathan
    Wang, Steven
    Williams, Abeda
    Singh, Vikram
    Thomas, Adrian
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (06) : 677 - 689
  • [48] Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection
    Simpson, KN
    Luo, MP
    Chumney, E
    Sun, E
    Brun, S
    Ashraf, T
    HIV CLINICAL TRIALS, 2004, 5 (05): : 294 - 304
  • [49] Cost-effectiveness of ceftazidime/avibactam versus colistin plus meropenem for treatment of carbapenemic-resistant enterobacteria infections in Chile
    Gutierrez, Magda A.
    Fandino, Cecil
    REVISTA CHILENA DE INFECTOLOGIA, 2021, 38 (01): : 7 - 14
  • [50] COLISTIN MONOTHERAPY VERSUS COLISTIN-PLUS REGIMENS FOR TREATMENT OF MULTI-DRUG RESISTANT NOSOCOMIAL PNEUMONIA IN CRITICALLY ILL PATIENTS
    Eagleson, Nikita
    Doshi, Neha
    Cook, Charles
    Murphy, Claire
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U34 - U34
12345